BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16125299)

  • 1. IL-18 E42A mutant is resistant to the inhibitory effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune response.
    Lee KA; Cho KJ; Kim SH; Shim JH; Lim JS; Cho DH; Song MS; Dinarello CA; Yoon DY
    Cancer Lett; 2005 Nov; 229(2):261-70. PubMed ID: 16125299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
    Subbaramaiah K; Dannenberg AJ
    Cancer Res; 2007 Apr; 67(8):3976-85. PubMed ID: 17440114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer.
    Lee DW; Anderson ME; Wu S; Lee JH
    Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1316-23. PubMed ID: 19075129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis.
    Divya CS; Pillai MR
    Mol Carcinog; 2006 May; 45(5):320-32. PubMed ID: 16526022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells.
    Lee SJ; Cho YS; Cho MC; Shim JH; Lee KA; Ko KK; Choe YK; Park SN; Hoshino T; Kim S; Dinarello CA; Yoon DY
    J Immunol; 2001 Jul; 167(1):497-504. PubMed ID: 11418688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes.
    Nees M; Geoghegan JM; Hyman T; Frank S; Miller L; Woodworth CD
    J Virol; 2001 May; 75(9):4283-96. PubMed ID: 11287578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
    Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
    Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix.
    Song SH; Lee JK; Seok OS; Saw HS
    Gynecol Oncol; 2007 Mar; 104(3):732-8. PubMed ID: 17188341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells.
    Lea JS; Sunaga N; Sato M; Kalahasti G; Miller DS; Minna JD; Muller CY
    Reprod Sci; 2007 Jan; 14(1):20-8. PubMed ID: 17636212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells.
    Rampias T; Sasaki C; Weinberger P; Psyrri A
    J Natl Cancer Inst; 2009 Mar; 101(6):412-23. PubMed ID: 19276448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
    Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
    Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16.
    Liu HC; Chen GG; Vlantis AC; Tse GM; Chan AT; van Hasselt CA
    J Cell Biochem; 2008 Mar; 103(4):1125-43. PubMed ID: 17668439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pro-angiogenic factors stimulated by human papillomavirus type 16 E6 and E7 protein in C33A and human fibroblasts.
    Xi L; Wang S; Wang C; Xu Q; Li P; Tian X; Wu P; Wang W; Deng D; Zhou J; Ma D
    Oncol Rep; 2009 Jan; 21(1):25-31. PubMed ID: 19082439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha- and betapapillomavirus E6/E7 genes differentially modulate pro-inflammatory gene expression.
    De Andrea M; Mondini M; Azzimonti B; Dell'Oste V; Germano S; Gaudino G; Musso T; Landolfo S; Gariglio M
    Virus Res; 2007 Mar; 124(1-2):220-5. PubMed ID: 17079045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins.
    Havard L; Rahmouni S; Boniver J; Delvenne P
    Virology; 2005 Jan; 331(2):357-66. PubMed ID: 15629778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells.
    Rincon-Orozco B; Halec G; Rosenberger S; Muschik D; Nindl I; Bachmann A; Ritter TM; Dondog B; Ly R; Bosch FX; Zawatzky R; Rösl F
    Cancer Res; 2009 Nov; 69(22):8718-25. PubMed ID: 19887612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development.
    Routes JM; Ryan S; Li H; Steinke J; Cook JL
    Virology; 2000 Nov; 277(1):48-57. PubMed ID: 11062035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.